Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and Tolerability of VLPCOV-U-01 SARS-CoV-2 Vaccine in Healthy Adults
jRCT2051250250Phase 1Active, not recruiting
- Sponsor
- VLP Therapeutics Japan
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of VLPCOV-U-01 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by VLP Therapeutics Japan. Started Mar 2026; status: active, not recruiting.
02
Drugs
VLPCOV-U-01
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051250250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250250.